Wednesday, February 10, 2010, 12:49am EST - Canadian Markets open in 8 hours and 41 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Qiagen NV (QGEN)

 On Feb 9: 20.60 USD  Down 0.06 (0.29%)  
MORE ON QGEN
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Qiagen N.V. (NasdaqNM:QGEN) Delayed quote dataEdit
After Hours: 20.60 0.00 (0.00%) as of 4:31pm EST on 02/09/10
Last Trade: 20.60 USD
Trade Time: Feb 9
Change: Down 0.06 (0.29%)
Prev Close: 20.66
Open: 20.74
Bid: N/A
Ask: 21.00 x 100
1y Target Est: 24.75
Day's Range: 20.58 - 20.98
52wk Range: 14.32 - 23.71
Volume: 3,576,071
Avg Vol (3m): 1,265,240
Market Cap: 4.76B
P/E (ttm): 35.70
EPS (ttm): 0.58
Div & Yield: N/A (N/A%)
Qiagen NV (QGEN)
1d  5d  3m  6m  1y  2y  5y  max 
Free Annual Reports
 Add QGEN to Portfolio   Download Data

HEADLINES
• UPDATE - Qiagen profit beats estimate on demand for tests
at Reuters (Mon, Feb 8)
• QIAGEN Acquires Exclusive Licence for Key PI3K gene
PRNewswire (Mon, Feb 8)
• Q4 2009 Qiagen N.V. Earnings Release - Time Not Supplied
CCBN (Mon, Feb 8)
• QIAGEN Unit And Pfizer Enter Into An Agreement To Develop A Companion Diagnostic For Brain Tumor Patients
Business Wire (Thu, Feb 4)
• Incubators Spawn Ideas, Money for IBM, AOL
at TheStreet.com (Wed, Feb 3)
• Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9
PRNewswire (Tue, Feb 2)
• Molecular Diagnostics Industry Creates New Sector With High Growth And Rapid Valuation Formation Characteristics For Investors According To Industry Expert
Wall Street Transcript (Wed, Jan 27)
• Genomic Testing Systems Create Sustainable Competitive Advantage For Selected Medical Diagnostic Stocks According To Award Winning Equity Analyst
Wall Street Transcript (Mon, Jan 25)
• BioInformatics, LLC New Report - The Contract Research Market for Drug Discovery Technologies: Opportunities for Life Science Suppliers
PRNewswire (Wed, Jan 13)
• QIAGEN Acquires ESE GmbH
PRNewswire (Tue, Jan 12)
More Headlines for QGEN...
ANALYST
EPS Est (next year) (Dec-09) : 0.89
EPS Est (in 2 years) (Dec-10) : 0.98
Avg Rec (current)*: 2.1
PEG Ratio: 1.10
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Qiagen N.V. provides technologies and products for preanalytical sample preparation and linked molecular assay solutions worldwide. Its sample technologies are used to collect, stabilize, isolate, and purify deoxyribonucleic acid (DNA), ribonuclei...

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices